Skip to main content

Oxford Expression Tech, Eden Biodesign Form Co-marketing Pact

NEW YORK (GenomeWeb News) — Oxford Expression Technologies and Eden Biodesign have struck a co-marketing agreement to serve pharmaceutical researchers involved in protein expression.

Under the agreement, OET will offer access to Eden Biodesign's process development, clinical trial current good manufacturing practice services. Eden Biodesign's customers, in turn, will be able to use OET's range of baculovirus capabilities for their individual protein expression requirements. In particular, Eden's customers will have access to OET's experience in troubleshooting baculovirus expression and the use of its flashback technology for increasing protein yield in difficult to express proteins.

OET was founded in 2007 by a collaboration between Oxford Brookes University and the Natural Environment Research Council to provide custom proteins for research purposes.

Eden Biodesign is focused on guiding clients through process development, manufacturing, regulatory and technology transfer challenges.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.